414 results on '"Hasford, J"'
Search Results
2. Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugs
3. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
4. A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction
5. In-hospital fall-risk screening in 4,735 geriatric patients from the LUCAS project
6. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
7. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
8. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
9. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
10. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
11. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
12. Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed
13. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
14. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
15. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia
16. The LUCAS* consortium: Objectives of interdisciplinary research on selected aspects of ageing and health care for older people in an urban community
17. LONG-ACTING BETA-2-ADRENOCEPTOR AGONISTS AND ANTICHOLINERGIC DRUGS: DRUG UTILISATION AND OFF-LABEL USE IN PAEDIATRIC PATIENTS LIVING IN BAVARIA (GERMANY): 239
18. CHANGES IN DRUG PRESCRIPTIONS AFTER THE SMART TRIAL - SECONDARY DATA ANALYSIS OF BAVARIAN ASTHMA PATIENTS: 197
19. ADRS LEADING TO HOSPITALISATION CAUSED BY SELFMEDICATION - RESULTS FROM A GERMAN LONG-TERM, OBSERVATIONAL STUDY: 178
20. Cytogenetic response to prior treatment with interferon-α is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia
21. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies
22. Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia
23. The German competence network ‘Acute and chronic leukemias’
24. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia – prospective long-term results from a randomized-controlled trial
25. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon α
26. Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea
27. Design and implementation of a common drug information database for a university hospital
28. German Multicenter Study Group for Adult ALL (GMALL): recruitment in comparison to ALL incidence and its impact on study results
29. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
30. A population-based European cohort study of persistence in newly diagnosed hypertensive patients
31. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
32. Data from the German-Austrian-Suisse MDS registry (D-A-CH MDS registry): V954
33. 12 month molecular response < 1% BCR-ABL (IS) is associated with improved overall and progression-free survival in CML patients: V635
34. Superior CMR-rates with tolerability-adapted imatinib 800 mg vs. 400 mg vs. 400 mg + IFN in CML: The randomized German CML-Study IV: V633
35. Therapy with imatinib in elderly CML patients (≥65 years): Results of the German CML-Study IV: V632
36. Coping with the new statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia: V636
37. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany
38. Confirmation of the mantle cell lymphoma international prognostic index (MIPI) in an independent prospective cohort: V679
39. Optimization of imatinib therapy by combination. Final results of the pilot phase of the randomized German CML Study IV: V279
40. High dose imatinib 800mg induces higher major molecular response (MMR) rates than imatinib 400 mg ± IFN in newly diagnosed BCR/ABL positive chronic phase CML: A randomized comparison of the German CMLStudy IV: V276
41. Evolution of blast crisis (BC) in chronic myeloid leukemia (CML) in the imatinib-era: A rare but early event; need for rapid detection. Results of the German CML Study IV.: V281
42. Persistence with asthma treatment is low in Germany especially for controller medication – a population based study of 483 051 patients
43. Optimization of Imatinib Therapy By Combination. 5 Year Survival and Response; Results of the Pilot Phase of the Randomized German CML Study IV: FV326
44. OPTIMIZATION OF IMATINIB THERAPY BY COMBINATION, DOSE ESCALATION AND TRANSPLANTATION. DESIGNED FIRST INTERIM ANALYSIS OF THE RANDOMIZED GERMAN CML STUDY IV: V54
45. Allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) in the imatinib era: Evaluation of its impact within a subgroup of the German CML Study IV: V56
46. Early Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term PFS and EFS in CP-CML - an Interim Analysis of the Randomized German CML Study IV.: V55
47. PREVENTABILITY OF ADVERSE DRUG REACTIONS LEADING TO HOSPITAL ADMISSION — ASSESSMENT OF INTER-RATER VARIABILITY WITHIN THE NETWORK OF REGIONAL PHARMACOVIGILANCE CENTERS: 5
48. PATIENT SELF-MEDICATION AND SERIOUS ADVERSE DRUG REACTIONS (ADRS): 3
49. MODULATORS FOR ELECTRONIC RISK PREDICTION OF ADVERSE DRUG EVENTS - PATIENT CHARACTERISTICS IN DRUG-DRUG INTERACTIONS AND DOSE ADJUSTMENTS: 80
50. A THRESHOLD VALUE TO INCREASE THE CLINICAL RELEVANCE OF OVERDOSE ALERTS: 79
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.